

Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk

Brett M. Reid¹, Jennifer B. Permut¹, Y. Ann Chen¹, Brooke L. Fridley¹, Edwin S. Iversen², Zhihua Chen¹, Heather Jim¹, Robert A. Vierkant³, Julie M. Cunningham³, Jill S. Barnholtz-Sloan⁴, Steven Narod⁵, Harvey Risch⁶, Joellen M. Schildkraut⁷, Ellen L. Goode³, Alvaro N. Monteiro¹, and Thomas A. Sellers¹



Abstract

Background: Germline DNA copy number variation (CNV) is a ubiquitous source of genetic variation and remains largely unexplored in association with epithelial ovarian cancer (EOC) risk.

Methods: CNV was quantified in the DNA of approximately 3,500 cases and controls genotyped with the Illumina 610k and HumanOmni2.5M arrays. We performed a genome-wide association study of common (>1%) CNV regions (CNVRs) with EOC and high-grade serous (HGSOC) risk and, using The Cancer Genome Atlas (TCGA), performed *in silico* analyses of tumor-gene expression.

Results: Three CNVRs were associated ($P < 0.01$) with EOC risk: two large (~100 kb) regions within the 610k set and one small (<5 kb) region with the higher resolution 2.5M data. Large CNVRs included a duplication at *LILRA6* (OR = 2.57; $P = 0.001$) and a deletion at *CYP2A7* (OR = 1.90; $P = 0.007$) that were strongly associated with HGSOC risk (OR = 3.02; $P = 8.98 \times 10^{-5}$). Somatic *CYP2A7* alterations correlated with

EGLN2 expression in tumors ($P = 2.94 \times 10^{-47}$). An intronic *ERBB4/HER4* deletion was associated with reduced EOC risk (OR = 0.33; $P = 9.5 \times 10^{-2}$), and somatic deletions correlated with *ERBB4* downregulation ($P = 7.05 \times 10^{-5}$). Five CNVRs were associated with HGSOC, including two reduced-risk deletions: one at 1p36.33 (OR = 0.28; $P = 0.001$) that correlated with lower *CDK11A* expression in TCGA tumors ($P = 2.7 \times 10^{-7}$), and another at 8p21.2 (OR = 0.52; $P = 0.002$) that was present somatically where it correlated with lower *GNRH1* expression ($P = 5.9 \times 10^{-5}$).

Conclusions: Though CNV appears to not contribute largely to EOC susceptibility, a number of low-to-common frequency variants may influence the risk of EOC and tumor-gene expression.

Impact: Further research on CNV and EOC susceptibility is warranted, particularly with CNVs estimated from high-density arrays.

Introduction

Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer-related death among women in North America (1). Because most women are diagnosed at advanced stages, better early detection and intervention is needed (1). Genome-wide association studies (GWAS) have identified thirty-nine common allelic variations associated with EOC susceptibility (2), but these variants explain only a modest fraction of heritability (3), thus

more such loci likely exist. Exploration of other sources of DNA variation is warranted.

High-throughput genome technologies have revealed that the human genome contains substantial structural variation. An estimated 10%–13% of DNA content can be spanned by copy number variation (CNV), segments of DNA one kilobase or larger in length, that differ from a reference genome (4, 5). Germline CNV can be inherited or occur *de novo* (6) and predispose to an array of complex diseases including familial and sporadic types of cancer (7). The contribution of CNV to EOC risk remains largely unexplored.

Our group has previously evaluated whether inherited CNVs were associated with overall survival among 1,056 women with EOC; no associations achieved statistical significance after adjustment for multiple comparisons (8). Almost all studies evaluating CNV and EOC risk have been conducted among *BRCA1* carriers or women with hereditary breast-ovarian cancer syndrome (9–11). The largest study to-date included 357 EOC cases and 1,962 nonovarian cancer-affected *BRCA1* carriers from The Consortium of Investigators of Modifiers of *BRCA1/BRCA2* (CIMBA), where a validated deletion in *CYP2A7* was associated with decreased EOC risk (10). An analysis of The Cancer Genome Atlas (TCGA) compared the germline-somatic landscape in exomes of 429 high-grade serous (HGSOC) cases to 557 controls (12). However, copy number analysis was limited to *BRCA1*, *BRCA2*, and *TP53* (12). This study represents the first large-scale genome-wide

¹Moffitt Cancer Center and Research Institute, Tampa, Florida. ²Duke University Medical Center, Durham, North Carolina. ³Mayo Clinic College of Medicine, Rochester, Minnesota. ⁴Case Comprehensive Cancer Center, Cleveland, Ohio. ⁵Center for Research in Women's Health, Toronto, Ontario, Canada. ⁶Yale School of Public Health, New Haven, Connecticut. ⁷University of Virginia, Charlottesville, Virginia.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: Thomas A. Sellers, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Phone: 813-745-1315; Fax: 813-449-8126; E-mail: thomas.sellers@moffitt.org

Cancer Epidemiol Biomarkers Prev 2019;28:1117–26

doi: 10.1158/1055-9965.EPI-18-0833

©2019 American Association for Cancer Research.

analysis of germline CNV evaluating associations with EOC risk among unselected women from the general population.

Methods

Study population

Our GWAS of EOC utilized two genotyping platforms. Four case-control studies from Mayo Clinic (Rochester, MN), Duke University (Durham, NC), University of Toronto (Toronto, Canada), and Moffitt Cancer Center (Tampa, FL) used the Illumina 610-quad Beadchip Array ("610k"). An independent sample of cases and controls from Mayo Clinic was genotyped on the Illumina HumanOmni2.5M-8 Beadchip ("2.5M"). Both GWAS sets included patients with incident, pathologically confirmed primary EOC, either borderline or invasive, aged 20 or above. DNA samples from women having less than 80% European ancestry were excluded (13). Full study details have been previously published (14, 15).

CNV calling and quality control

CNV segmentation was performed with PennCNV software (16) on probe-level B allele frequency (BAF) and \log_2 R ratio (LRR) for autosomal SNPs mapped to GRCh37 (hg19), with adjustment for local GC content responsible for signal fluctuations (17). Segments spanning at least 3 probes and confidence scores >10 were retained. To reduce possible batch effects or poor quality intensity data, we excluded samples with outliers [$>\text{median} + 1.5$ interquartile range (IQR)] for LRR SD, BAF drift, GC wave factor, and number of CNV calls. In total, 856 (23%) of the 610k array samples and 219 (22%) of the 2.5M array samples were excluded. The dataset used for this analysis will be made available through dbGAP under study accession phs001133.v1.p1.

Common CNV regions and association testing

CNV regions (CNVRs) were defined using the CNVRuler tool (18) that constructs CNVRs by merging CNV segments that overlap by at least 1 bp and trims any rare, long CNV. Logistic regression was used to compare CNVR status (deletion/no deletion; duplication/no duplication) between cases and controls that occurred with $>1\%$ frequency among all samples in a set. To adjust for population stratification, eigenvectors were calculated from a matrix of CNVR status and the first principal component was included as a covariate of regression (Supplementary Fig. S1). Site, age, and experimental batch are known sources of bias (19) but none affected CNVR estimates and these were not retained in the risk model. As a sensitivity analysis for the CNVR merge method, we also employed ParseCNV (20) that performs SNP-level association testing and merges significant SNPs into risk-associated CNVRs. CNV mapping studies suggest that deletions are poorly tolerated and under negative selection whereas duplications are less likely to be pathogenic and are often under positive selection, which drives evolution of many gene families (21). Thus, for both analytic approaches, deletions and duplications were analyzed separately. Risk associations are reported for CNVRs that reached $P < 0.01$ significance threshold. We excluded T-cell receptor (TCR) and immunoglobulin heavy (IGH) chain genomic regions from analyses as these undergo V-(D)-J recombination in lymphocytes and can result in detection of somatic CNVs rather than inherited, germline CNV, which is the focus of this study (22, 23). These regions included

TCR alpha and delta of chromosome 14 (chr14:22090057-23021075 and chr14:22891537-22935569, respectively), beta and gamma on chromosome 7 (chr7:141998851-142510972 and chr7:38279625-38407656, respectively), and IGH regions on chromosomes 14 and 16 (chr14:106032614-107288051 and chr16:33740716-33741266).

Integration of CNV and tumor transcriptome using TCGA

To explore the correlation of copy number and gene expression, we obtained copy number segments, gene-level Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values from RNA sequencing, and CpG island methylation data for 571 HGSOC cases from TCGA (24) that had germline CNV quantified from either blood or normal tissue samples. CNV segments were estimated from SNP 6.0 array using circular binary segmentation and were limited to those with a minimum of three probes and <10 MB in size. Samples with a high number of calls ($>\text{median} + 1.5$ IQRs) were excluded. We defined deletions as segments with mean copy number ≤ 0.3 and amplifications as those > 0.3 . We employed multivariate linear regression to model both CNV and somatic copy number alterations (SCNA) in the cancer genome (diploid, deletion, duplication) on mRNA expression level (\log_2 transformed) in tumor tissue. *P* values were calculated with the likelihood ratio statistic. For each gene, the effect of CpG methylation was regressed out, as described previously (25). Statistical analyses were performed in R (www.r-project.org).

Results

Table 1 summarizes the clinical characteristics and copy number distribution of 2,818 subjects (1,368 cases) genotyped with the 610k array and 792 subjects (449 cases) genotyped with the 2.5M array after applying quality control (QC) exclusions. Cases were slightly older than controls on average and the majority had serous tumors. Most (75%) of the CNV calls in the 610k array data were deletions, whereas the majority (59%) in the 2.5M set were duplications. The average number and length of deletions and duplications were similar between cases and controls (Table 1). The distribution of CNV in the 610k set was largely similar across the five main histotypes of EOC and by stage at diagnosis, although advanced stage endometrioid cases ($n = 50$) averaged a significantly higher number of deletions ($P = 0.0003$; Supplementary Table S1). Although 2.5M sample sizes were too small to investigate stage of disease, low-grade serous cases ($n = 43$) did average a significantly lower number of duplications ($P = 0.002$; Supplementary Table S2).


CNVRs were constructed by merging overlapping CNV calls across individuals in a study set, separately for deletions and duplications. In the 610k set, there were 7,384 CNVRs that included 348 regions occurring in $\geq 1\%$ of subjects (denoted as common CNVRs henceforth), 3,105 rare regions ($<1\%$), and 3,931 regions detected in a single individual (singletons). In the 2.5M set, CNV calls merged into 3,732 CNVRs: 624 common regions, 972 rare regions, and 2,136 singletons. Notably, the majority ($>80\%$) of CNV was rare ($<1\%$) or singletons. Rare CNV calls trended higher for cases than controls in both array sets but the results were not statistically significant (Supplementary Table S3).

CNVR size distributions differed between array sets, likely reflecting differences in probe density (Fig. 1). CNVRs in the 2.5M set spanned shorter genomic regions (median = 23 kb)

Table 1. Study participant characteristics and CNV distributions

	610k Array N = 2818		P ^a	2.5M Array N = 792		P ^a
	Case	Control		Case	Control	
N	1,368	1,450		449	343	
Age						
Mean (range)	60.1 (26-91)	57.7 (20-90)	<0.001	62.2 (20-88)	58.2 (22-93)	<0.001
Study site						
Minnesota region (Mayo)	325	467		449	343	
North Carolina (Duke)	406	553		0	0	
Tampa Bay (Moffitt)	152	139		0	0	
Toronto (U of Toronto)	485	291		0	0	
Histotype (%)						
Serous	825 (60%)			346 (77%)		
High grade	410 (30%)			303 (67%)		
Low grade/LMP	121 (9%)			43 (10%)		
Unknown	294 (21%)			0		
Endometrioid	241 (18%)			30 (7%)		
Mucinous	63 (5%)			28 (6%)		
Clear cell	112 (8%)			15 (3%)		
Mixed cell	38 (3%)			25 (6%)		
Other	89 (7%)			5 (1%)		
CNV segments (No.)						
All	30,877	33,626		28,578	21,929	
Deletions	23,532 (76%)	25,028 (74%)		11,947 (42%)	8,821 (40%)	
Duplications	7,345 (24%)	8,598 (26%)		16,631 (58%)	13,108 (60%)	
CNV segments (Mean)						
All	22.6	23.2	0.93	63.7	63.9	0.63
Deletions	17.2	17.3	0.56	26.6	25.7	0.06
Duplications	5.4	5.9	1.00	37.0	38.2	0.92
Average CNV length (Kb)						
All	77	80	0.99	48	49	0.93
Deletions	55	54	0.34	25	26	0.73
Duplications	144	146	0.64	65	66	0.77

^aMean age was compared between cases and controls with the Student *t* test. Empirical *P* values are reported for difference in CNV average number of segments and difference in average CNV length based on 10,000 permutations.



compared with the 610k set (median = 246 kb) where regions >200 kb in size comprised the majority (70%) of CNVRs. Most of the common CNVRs in the 610k set ($N = 271$, 78%) were detected at least once within the higher resolution 2.5M array set and, conversely, 383 (61%) in the 2.5M set were detected at least once in the 610k set. We limited CNVRs to those detected within both array sets and excluded genomic regions that are somatically deleted in lymphocytes and are not likely to be inherited, germline CNV (see Methods). In total, 189 deletion and 74 duplication CNVRs in the 610k set and 252 deletion and 125 duplication CNVRs in the 2.5M set were analyzed for association with EOC risk.

Common CNV regions and EOC risk

CNV associations with EOC risk overall and with HGSOE are shown in Fig. 2. Differences in copy number between all EOC cases and controls were detected ($P < 0.01$) at three common CNVRs (Table 2). Two CNVRs spanning approximately 100 kb

Figure 1. Common CNV regions generated from two SNP-array datasets. CNVRs were compared between 2.5M and 610k array sets. Bar charts, number of deletion and duplication CNVRs that were common in each set. The overlap between sets is denoted by stacked bars.




Figure 2.

Manhattan plots for association analyses between common CNVR and EOC risk. Logistic regression was conducted for common CNVRs that were detected by both arrays. Separate analyses for deletions (red) and duplications (blue) in both the 610k (filled points) and 2.5M (outline points) array sets were conducted for all epithelial risk (circle) and high-grade serous specific risk (triangle).

each were associated with EOC risk within the 610k population and a third, substantially smaller CNVR <5 kb in length was associated with risk in the 2.5M analysis. HGSOC-specific analysis showed that all three EOC risk-associated CNVRs were also associated with HGSOC (Table 3). An additional four CNVR in the 610k analysis and one CNVR in the 2.5M analysis were associated with HGSOC risk ($P < 0.01$) that were not identified in the overall EOC analysis. All CNVRs were detected in both array sets albeit frequencies varied between sets and comparable regions were substantially smaller in the 2.5M set (Supplementary Table S4). In addition, risk-associated CNVRs were compared

with the Database of Genomic Variants and shown to overlap gold standard copy number variants (Supplementary Table S5).

Within the analysis of all invasive EOC, a duplication region at 19q13.42 within the human leukocyte receptor cluster was associated with increased risk of EOC in the 610k set ($P = 0.001$; OR = 2.57). Duplications within this CNVR spanned leukocyte immunoglobulin like receptor A6 (*LILRA6*) and occurred with low frequency (2%). The CNVR was more common in 2.5M subjects (28%) but frequency did not differ by disease status ($P = 0.89$; OR = 0.98). A second CNVR identified in the 610k set

Table 2. Association of common germline CNVRs with EOC susceptibility

Array (N cases)	Locus	CNV type	Gene	CNVR (KB)	Merged CNVR ^a			SNP-level CNVR ^b			
					Case/control, n (%)	P	OR (95% CI)	Tag SNP	Total SNPs	P	OR (95% CI)
610k (n = 1,368)	19q13.2	Del	<i>CYP2A7</i>	chr19:41341589-41433931 (92)	49 (4)/29 (2)	0.007	1.90 (1.19–3.03)	rs2545754	9	0.006	2.03 (1.22–3.36)
	19q13.42	Dup	<i>LILRA6</i>	chr19:54731679-54845802 (114)	39 (3)/17 (1)	0.001	2.57 (1.44–4.57)	rs11672654	11	0.01	5.87 (1.53–22.57)
2.5M (n = 449)	2q34	Del	<i>ERBB4</i>	chr2:213187034-213191389 (4)	8 (2)/18 (5)	0.0095	0.33 (0.14–0.76)	kgp5655115	12	0.008	0.33 (0.15–0.75)

Abbreviation: CI, confidence interval.

^aCNVR was defined by overlapping CNV segments across subjects. Coordinates are mapped to human genome build 37 (hg19). *P* values are from logistic regression adjusted for the first principal component.

^bCNVR was defined as region with significant SNP-level statistics, and *P* value reported is from Fisher exact test comparing deletion/no deletion or duplication/no duplication. All epithelial OC versus controls are reported.

Table 3. Association of common germline CNVRs with HGSOC susceptibility

Array (N cases)	Locus	CNV type	Gene(s)	CNVR (KB) ^a	Merged CNVR			SNP-level CNVR			
					Case/ control, n (%)	P	OR (95% CI)	Tag SNP	Total SNPs	P	OR (95% CI)
610k (n = 410)	1p36.33	Del	ACAP3, CPSF3L, DVL1, GLTPD1, MXRA8, PUSL1, TASIR3 ^b	Chr1:943468- 1706160 (763)	7 (2)	0.001	0.28 (0.13–0.60)	rs3737717	13	0.001	0.31 (0.15–0.62)
					84 (6)						
	1p13.3	Del	Intergenic	Chr1:111370372- 111391381 (21)	23 (6) 40 (3)	0.007	2.07 (1.21–3.51)	rs6677356	6	0.008	2.09 (1.21–3.60)
	8p21.2	Del	DOCK5	Chr8:24931313- 25101936 (171)	27 (7) 168 (12)	0.002	0.52 (0.34–0.79)	cnvi0001694	7	0.003	0.54 (0.36–0.81)
	12p11.21	Dup	RP11-428G5.5	Chr12:31975730- 32068877 (93)	19 (5) 32 (2)	0.0098	2.14 (1.20–3.82)	rs1259725	27	0.015	2.15 (1.16–3.98)
2.5M (n = 303)	19q13.2	Del	CYP2A7	chr19:41341589- 41433931 (92)	24 (6) 29 (2)	8.98E-05	3.02 (1.74–5.25)	rs2545754	9	2.79E-05	3.54 (1.96–6.39)
	19q13.42	Dup	LILRA6	chr19:54731679- 54845802 (114)	15 (4) 17 (1)	0.001	3.16 (1.56–6.39)	rs11672654	8	0.004	2.98 (1.42–6.27)
	2q34	Del	ERBB4	chr2:213187034- 213191389 (4)	3 (1) 18 (5)	0.005	0.18 (0.05–0.60)	kgp5655115	12	0.003	0.18 (0.06–0.56)
	5p15.2	Del	Intergenic	Chr5:12812336- 12888815 (76)	55 (18) 36 (10)	0.005	1.91 (1.22–3.01)	kgp22267001	3	0.009	1.85 (1.17–2.94)

Abbreviation: CI, confidence interval.

^aCNVR was defined by overlapping CNV segments across subjects. *P* values are from logistic regression adjusted for the first principal component.

^bCNV segments centered on the reported genes, which fell within the SNP-level significance region.

was a deletion at 19q13.2 spanning cytochrome P450 family 2 subfamily A member 7 (*CYP2A7*) and the downstream, intergenic region ($P = 0.007$; OR = 1.90). The deletion region was similarly common in the 2.5M population (6%) but not associated with EOC risk ($P = 0.27$; OR = 0.71). Finally, a small, 4 kb deletion CNVR within intron 1 of erb-b2 receptor tyrosine kinase 4 (*ERBB4/HER4*) at 2q34 was associated with reduced EOC risk ($P = 0.0095$; OR = 0.33) in the 2.5M data. CNV within the boundaries of this region were rare (<1%) in the 610k analysis and not associated with risk ($P = 0.47$; OR = 1.60).

The HGSOC risk analysis was limited to a subset of 410 cases in the 610k array set and 303 cases in the 2.5M array set. The increase in EOC risk for *CYP2A7* deletion carriers in the 610k set was stronger for HGSOC-specific risk ($P = 8.98 \times 10^{-5}$; OR = 3.02), although it was not associated with HGSOC risk in the 2.5M analysis ($P = 0.18$). The CNVRs at *LILRA6* and *ERBB4* showed slightly stronger risk associations with HGSOC (OR = 3.16 and 0.18, respectively).

Two relatively large deletion regions were associated with lower risk of HGSOC: one spanning much of 1p36.33 ($P = 0.001$; OR = 0.28) and the other a 171 kb deletion at 8p21.2 ($P = 0.002$; OR = 0.52). The CNVR at 1p36.33 spanned an approximately 750 kb region, although most deletions were located within a smaller approximately 60 kb region where multiple genes reside including *disheveled segment polarity protein 1* (*DVL1*). While large, the 8p21.2 deletion region solely contained the transcription start site (TSS) and sequence for *dedicator of cytokinesis 5* (*DOCK5*) and no other coding features. Both deletions were also detected with the 2.5M array set with the 1p36.33 CNVR smaller and centered on *ATPase family, AAA domain containing 3B* (*ATAD3B*) rather than *DVL1* and the 8p21.2 CNVR concurring with the TSS region of *DOCK5*. Both 2.5M CNVR associations were not statistically

significant (1p36.33: $P = 0.71$, OR = 0.80; 8p21.2: $P = 0.61$, OR = 1.13).

Three other CNVRs were associated with increased risk of HGSOC. First, duplications of a 100 kb region at 12p11.21 that contained lincRNA *RP11-428G5.5* occurred in twice as many HGSOC cases as controls ($P = 9.8 \times 10^{-3}$; OR = 2.14). This CNVR was also detected in 3% of 2.5M subjects but was not associated with risk ($P = 0.36$; OR = 0.62). A smaller 21 kb intergenic region at 1p13.3 revealed deletions among 6% of HGSOC cases and 3% of controls ($P = 0.007$; OR = 2.07). These deletions were 22 kb upstream to ubiquitously expressed cell-surface protein *CD53 molecule*. The same deletion region was detected with the 2.5M array but only present in one control and no HGSOC cases. Finally, a more common intergenic deletion CNVR at 5p15.2 was associated with increased HGSOC risk in the 2.5M set (18% in cases, 10% in controls, $P = 0.005$; OR = 1.91). Deletions within this region were detected in ten HGSOC cases and five controls in the 610k set ($P = 0.30$; OR = 1.76).

Our analysis of CNVRs was based on the assignment of a consensus boundary defined by merging individual segments. To determine whether this affected downstream association analyses, we conducted a sensitivity analysis that identified regions where SNP-level copy number was significantly associated with EOC risk rather than solely testing in predefined regions. All CNVRs associated with EOC risk in our primary analysis were also detected using the SNP-based CNVR approach, with notably higher risk estimates at the CNVR containing *LILRA6* (Table 2), and more similar estimates for HGSOC-specific risk associations (Table 3). In addition, CNVR boundaries in our primary analysis were established by merging deletions and duplications separately. As an alternative approach, we merged segments irrespective of CNV type, which defined gain only, loss only, and mixed type

regions. Consequently, CNVR boundaries were altered from our primary analysis; however, risk associations remained significant for all regions and were strengthened for the 8p21.2 (*DOCK5*) association with EOC risk ($P = 0.004$; OR = 0.69; Supplementary Tables S6 and S7). Analysis of mixed type CNV (deletion or duplication vs. diploid) did not identify any additional common CNVR associated with EOC risk.

Association of risk CNVRs with transcription levels in tumor tissue

With the multilevel data available from TCGA, we sought to determine whether germline CNV within the risk-associated CNVRs correlated with primary tumor mRNA expression levels. This required careful consideration of SCNA as they are the most prevalent alteration in the cancer genome and are known to influence oncogene activation and tumor suppressor gene inactivation in tumor tissues (26). Thus, within seven CNVRs, we quantified (i.e., deletion/diploid/duplication) CNV of the germline DNA and focal SCNA in the tumor and estimated their independent effects on *cis*-mRNA gene expression in 382 HGSOC

cases from TCGA having both CNV and RNA-sequencing data. We excluded 5p15 as no mRNA sequences were within 500 kb of the CNVR.

CNVs were detected with common frequencies (1%–41%) within the risk-associated regions for the TCGA set of HGSOC cases, which was derived from a separate platform and segmentation algorithm, increasing our confidence in their validity (Fig. 3A). These regions also contained a high frequency of somatic alterations in the tumor genome (16%–26%), excluding the 1p36 region that was diploid in all HGSOC tumors. CNV at 1p36 was the only region significantly associated with expression of mRNA after adjustment for SCNA (Fig. 3B). Eleven percent ($N = 42$) of TCGA cases had germline deletions at the 1p36 CNVR and tumor expression in these subjects was significantly down-regulated for *cyclin dependent kinase 11A* (*CDK11A*) compared with noncarriers [fold change (FC) = -1.8 , $P = 2.68 \times 10^{-7}$].

SCNA at the risk CNVRs generally spanned large segments of chromosomal bands but only a subset (44/110) of amplified/deleted genes correlated ($P < 0.05$ and $FC > 1.5$) with altered gene expression (Supplementary Table S8; Fig. 3C). Four regions




Figure 3.

Correlation of risk-associated CNVRs with mRNA expression in 382 primary ovarian tumors. Linear regression was used to estimate associations of both germline CNV and SCNA in the tumor genome with gene expression in tumor tissue. Barplots for frequency of CNV and SCNA by type of alteration (A), boxplots for expression of genes that were associated with CNV at 1p36 (B), and most correlated with SCNA at six risk-associated CNVRs (C).

(1p13, 2q34, 19q13.2, and 19q13.42) exhibited both deletions and duplications in cancer genomes while 8p21.2 had only deletions and 12p11.21 had only duplications. Across all characterized genes, the most statistically significant association was between tumor copy number at 19q13.2 and *egl-9 family hypoxia inducible factor 2* (*EGLN2*) expression ($FC_{Del} = 1.7$, $P = 2.94 \times 10^{-47}$); 20 other genes were also correlated with copy number at this region. Notably, deletion of *CYP2A7*, the location of the risk-associated CNVR, was not associated with *CYP2A7* or *CYP2A6* expression ($P = 0.09$ and 0.08 , respectively). On the basis of a public catalog of enhancers, the *CYP2A7* CNVR overlaps an enhancer region in normal ovarian tissue predicted to affect the expression of *EGLN2* (27). Somatic deletion of the enhancer region cooccurred with deletion of *EGLN2* in all SCNA carriers except one. SCNA at the 19q13.42 region was correlated with 12 genes and most significantly with *pre-mRNA processing factor 31* (*PRPF31*), a component of spliceosome complex, and *TCF3 fusion partner* (*TFPT*), which were significantly overexpressed when duplicated ($FC_{Dup} = 2.0$, $P = 1.21 \times 10^{-30}$ and $FC_{Dup} = 2.5$, $P = 7.1 \times 10^{-27}$, respectively). Expression of the immunoglobulin superfamily of genes clustered at this region, which include leukocyte immunoglobulin-like receptors and killer cell inhibitory receptors, was not associated with copy number ($P > 0.05$). The intergenic 21 kb CNVR at 1p13.3 was somatically altered in 16% of tumors and associated with expression of four genes. Tumors with somatic deletions averaged approximately two-fold lower expression for *choline/ethanolamine phosphotransferase 1* (*CEPT1*; $FC_{Del} = -2.02$; $P = 9.58 \times 10^{-22}$), *DNA damage regulated autophagy modulator 2* (*DRAM2*; $FC_{Del} = 1.9$; $P = 1.18 \times 10^{-13}$), and *DENN domain containing 2D* (*DENN2D*; $FC_{Del} = 2.1$; $P = 2.75 \times 10^{-11}$). Risk-associated deletions at 2q34 were located within the first intron of *ERBB4* whose entire sequence spans >1MB in length. No other mRNAs are located within 500 kb of the CNVR. *ERBB4* somatic deletions were associated with a four-fold decrease in *ERBB4* expression ($FC_{Del} = 4.2$; $P = 4.67 \times 10^{-5}$).

SCNA at 8p21.2 and 12p11.21 were also common but showed specificity for one type of alteration. Amplifications at the 12p11 CNVR occurred in 17% of tumors and were associated with higher expression levels for four genes including two guanine exchange factors (*GEF*), *FYVE*, *RhoGEF*, and *PH domain containing 4* (*FGD4*; $FC_{Dup} = 1.5$; $P = 3.0 \times 10^{-8}$), and *DENN domain containing 5B* (*DENND5*; $FC_{Dup} = 1.7$; $P = 1.0 \times 10^{-3}$), that display highest expression in ovarian tissue (28). Only 2 tumors contained deletions within the 12p11.21 CNVR. The 8p21.2 region was deleted more frequently (23%) than all other risk regions but duplications rarely occurred ($N = 4$). Deletions at 8p21.2 were associated with downregulation of *gonadotropin-releasing hormone* (*GNRH1*; $FC_{Del} = -1.7$; $P = 5.86 \times 10^{-5}$) which is located 175 kb from the germline CNVR. The 8p21.2 germline deletion region spans both the TSS of *DOCK5* and upstream histone modifications consistent with an enhancer element in ovarian tissue (27).

Discussion

CNV is a major source of human genetic variation that contributes as much to interindividual differences as the more frequently studied SNP (4). Here, we describe a large genome-wide association study of CNV with EOC risk that used a comprehensive dual array design and supplemented with *in silico* functional follow-up. Two SNP array datasets provided complementary strengths; the 610k array set contributed discovery power with

its large sample size while the 2.5M set provided considerably higher resolution. Accordingly, we identified six relatively large CNV regions associated with EOC or HGSOC risk ($P < 0.01$) within the 610k array set and two smaller regions within the 2.5M set. In addition to limited power, the fewer detected differences and lack of replication with the 2.5M set may be due to the low frequency of variants, chance and sampling variation in the populations, and differential platform/probe CNV calling performance; it is probably a combination of these factors. By requiring CNVRs to be called by both platforms, our findings more likely reflect true variation rather than technical artifact, although type I error remains possible. Thus, we further detected and functionally characterized risk-associated CNVRs through analysis of TCGA data. The integration of both germline and somatic copy number with tumor transcription revealed associations that provided insight into the potential biological consequence of genomic copy number.

A large deletion at 1p36.33 was the only CNV independently associated with tumor transcription. Carriers were estimated to have an approximately 70% lower risk of EOC ($P = 0.001$) and corresponding analysis of tumor tissue showed lower expression of the cyclin-dependent kinase (CDK) *CDK11A* in carriers. *CDK11* has three isoforms involved in cell-cycle control (p58), transcriptional regulation (p110), and apoptotic signaling (p46; ref. 29). *CDK11-p58* is a centrosome-associated kinase expressed during the G_2 to M transition and inhibition induces cell-cycle arrest and apoptosis (30) while *CDK11-p110* positively regulates Hedgehog signaling and the Wnt/ β -catenin signaling cascade (29). Accordingly, *CDK* overexpression is a common feature of many cancer types and *in vitro* and *in vivo* *CDK11A/B* knockdown induces apoptosis in EOC cells (31). It is therefore plausible that the reduced risk of EOC observed for 1p36.33 deletion carriers is conferred through reduced *CDK11*-associated oncogenic signaling. Potentially complicating this theory, this CNVR was notably the only region that remained diploid in all HGSOC tumors. *CDK11-p58* promotes degradation of several steroid receptors such as androgen (32), vitamin D (33), and estrogen receptors (34), which inhibit migration and invasion of ER α -positive breast cancer cells (35). Thus, a similar suppressive role in progression of EOC may explain the lack of somatic amplification at 1p36.33.

The increased risk associated with a deletion at 19q13.2 containing *CYP2A7* (OR = 1.90) was the only finding that remained significant after adjustment for multiple hypothesis testing (Bonferroni corrected $P = 0.02$; FDR = 0.02). This same deletion region was recently identified in association with lower ovarian cancer risk among 2,500 *BRCA1* mutation carriers (CIMBA RR = 0.50; $P = 0.007$; ref. 10). *CYP2A7* is a pseudogene largely expressed in the liver where it promotes expression of *CYP2A6* (36) involved in the metabolism of nicotine and the tobacco-related procarcinogen nitrosamine (37). Genetic variation of *CYP2A6*, including a deletion, has been linked to a poor metabolizer phenotype and reduced risk of lung cancer in smokers (38). While altered enzymatic activity may similarly explain the reduced risk observed in *BRCA1* carriers, this study suggests a more complex relationship. Our *in silico* analyses identified *EGLN2*, an enzyme (aka PHD1) involved in cellular response to hypoxia (39), as the mRNA most significantly associated with *CYP2A7* SCNA ($P = 1.17 \times 10^{-49}$) but *CYP2A7* expression was not ($P = 0.09$). These data support regulation of *EGLN2* by an enhancer element at *CYP2A7* (27). Numerous other genes were also associated with SCNA, such as *melanoma inhibitory activity* (*MIA*), which was upregulated in

polyps of a germline *CYP2A7* deletion carrier in a recent study of familial adenomatous polyposis (40). *MIA* is a novel class of secreted proteins that interact with the extracellular matrix to promote the development, invasiveness, and metastases in melanoma as well as in pancreatic and gastric carcinomas (41, 42). Thus, germline *CYP2A7* deletions could have a role in promoting tumorigenesis and progression through epigenetic regulation of *cis*-genes such as *EGLN2* and *MIA* and this role may act secondarily to a separate, distinct role in metabolism that may be beneficial for *BRCA1* carriers. Altogether, the consistent detection of a *CYP2A7* locus deletion and its association with EOC risk warrants further investigation.

We identified five other CNVRs at nominal statistical significance but functional characterization of SCNA identified biological pathways pertinent to EOC risk. Of particular interest was the reduced EOC risk (OR = 0.52) associated with deletions at 8p21.2 where somatic deletions corresponded with lower expression of *GNRH1*. Gonadotropin releasing hormone (GnRH) induces pituitary synthesis and secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both of which are hypothesized to have an etiologic role in EOC (43). Although we did not observe an effect of germline CNV on tumor expression of *GNRH1*, it is tempting to hypothesize that deletions in this region may reduce systemic GnRH and thus mediate EOC risk associated with FSH/LH "excessive stimulation." We also observed frequent (23%) deletion of 8p21.2 in TCGA tumors yet rare occurrence of amplifications (<1%), which is consistent with previous studies reporting common 8p21.2-p21.3 deletion and loss of heterozygosity in ovarian tumors, particularly for serous histology and high-grade and chemoresistant disease (44–47). Published analyses of TCGA data identified 8p21.2 as one of the 40 most common focal deletions in ovarian cancer genomes and the deletions correlated with *GNRH1* expression (48). This indication of 8p21 as a tumor suppressor gene locus coincides with strong evidence that the extrapituitary, autocrine function of GnRH, involved in follicular development in the ovary (49), counteracts growth factor receptor signaling and exerts antiproliferative and antimotility effects in ovarian and other tumors (50). Our group previously observed SNPs within *GNRH1* that exhibited gene-level associations with increased HGSOE risk (51); we now report the first indication of an association between HGSOE risk and germline CNV at this region.

Other CNVs included deletion of *ERBB4* (HER4), a receptor tyrosine kinase in the EGFR family (e.g., EGFR, HER2) that is commonly mutated and highly expressed in many solid tumors including ovarian (52–54) where it portends chemotherapy resistance and poor survival (55–57). Consistent with these findings, *ERBB4* deletions associated with decreased EOC risk (OR = 0.33). Although germline deletions were intronic and their consequence on gene function is unknown, intronic SNPs in *ERBB4* affect its expression (58) and intronic CNV may also demonstrate this capability. SCNA at several risk CNVRs (1p13.3, 12p11.21, and 19q13.42) had multiple genic associations in pathways relevant to ovarian carcinogenesis including choline metabolism (*CEPT1*-1p13; ref. 59), regulation of autophagy and apoptosis (*DRAM2*-1p13, *TFPT*-19q13.2; refs. 60–62), and activation of cellular motility/migration in tumorigenesis (*FGD4*-12p11.21; ref. 63). Interestingly, somatic duplications at 19q13.42 were associated with expression of *PRPF3*, which has been previously associated with early HGSOE relapse (64). Although these transcriptome correlations are suggestive of tumor progression mechanisms, their implication in EOC risk is uncertain.

Although our study has by far the largest sample size to explore disease-associated CNV (7), analyses of GWAS for CNV suffer from reduced statistical power due to the rarity of CNV compared with SNPs and the statistically challenging detection of CNV from SNP arrays (65). Low frequency CNVRs (<5%) represented the majority (~82%) of variation identified in this study and this distribution has also been observed in a study of over 190,000 European adults where 92.4% of the CNVs were present in <1 in 1,000 samples and 99.4% of them occurred with <1% frequency (65). While a meta-analysis of the two array sets may improve statistical power, we opted for a stratified analysis with comparative evaluations given the large discrepancy in probe coverage and CNV detection between arrays. High false-negative and false-positive CNV calls can also limit statistical power. Although multiple detection algorithms are often used to increase sensitivity, we opted to use PennCNV alone, which called approximately 90% of all variants detected using four algorithms in a previous study (10). We controlled for false positives at multiple stages in our analytic pipeline, including stringent QC of logRatio, BAF, and sample outliers, which excluded approximately 25% of samples. Future studies should include technical validation of CNV such as qPCR and this may also allow more permissive QC criterion to be used to increase sample size. Considering these limitations, we reported EOC risk associations that reached a $P < 0.01$ threshold and did not adjust for multiple testing. As a discovery study, it was preferential to reduce type II error, and avoid missing possibly important findings, at the expense of increased type I error.

In summary, this large genome-wide study identified common CNV events in genomic regions that frequently undergo somatic alterations in ovarian tumors to promote progression. The risk associations together with *in silico* functional analyses highlight several novel genomic regions with biologically plausible mechanisms for EOC predisposition and pathogenesis. Replication of the findings in a larger study population profiled on the same platform is warranted. Since the initiation of this study, SNP array data from the Oncoarray (3) have become available and present opportunity for future CNV studies.

Disclosure of Potential Conflicts of Interest

H. Jim is a consultant/advisory board member for RedHill Biopharma and Janssen Scientific Affairs. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: B.M. Reid, J.B. Permuth, E.L. Goode, T.A. Sellers
Development of methodology: B.M. Reid
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.M. Cunningham, S. Narod, H. Risch, J.M. Schildkraut, T.A. Sellers
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B.M. Reid, Y.A. Chen, B.L. Fridley, Z. Chen, J.S. Barnholtz-Sloan, H. Risch, A.N. Monteiro
Writing, review, and/or revision of the manuscript: B.M. Reid, J.B. Permuth, Y.A. Chen, B.L. Fridley, E.S. Iversen, H. Jim, R.A. Vierkant, J.M. Cunningham, J.S. Barnholtz-Sloan, H. Risch, E.L. Goode, A.N. Monteiro, T.A. Sellers
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.S. Iversen, Z. Chen, H. Risch
Study supervision: E.S. Iversen, H. Risch

Acknowledgments

We thank all of the women who participated, along with all of the researchers, clinicians, and staff who have contributed to the participating studies. This work was supported by NIH R01 CA114343 and U19 CA148112 (to T.A. Sellers), R01 CA122443 (to E.L. Goode), R01 CA76016

(to J.M. Schildkraut), R01 CA106414 (to R. Sutphen), P30 CA15083 for the Mayo Clinic Genotyping Shared Resource, and Mayo Clinic Ovarian Cancer SPORE grant P50 CA136393.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 31, 2018; revised November 2, 2018; accepted March 28, 2019; published first April 4, 2019.

References

- American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018.
- Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. *Gynecol Oncol* 2017;147:705–13.
- Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 2017;49:680–91.
- Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. *Nature* 2006;444:444–54.
- MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The database of genomic variants: a curated collection of structural variation in the human genome. *Nucleic Acids Res* 2014;42:D986–D92.
- Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. *Nat Rev Genet* 2009;10:551–64.
- Krepischi AC, Pearson PL, Rosenberg C. Germline copy number variations and cancer predisposition. *Future Oncol* 2012;8:441–50.
- Fridley BL, Chalise P, Tsai YY, Sun Z, Vierkant RA, Larson MC, et al. Germline copy number variation and ovarian cancer survival. *Front Genet* 2012;3:142.
- Kuusisto KM, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J. Copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. *PLoS ONE* 2013;8:e71802.
- Walker LC, Marquart L, Pearson JF, Wiggins GAR, O'Mara TA, Parsons MT, et al. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *Eur J Hum Genet* 2017;25:432–8.
- Yoshihara K, Tajima A, Adachi S, Quan J, Sekine M, Kase H, et al. Germline copy number variations in BRCA1-associated ovarian cancer patients. *Genes Chromosomes Cancer* 2011;50:167–77.
- Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MDM, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. *Nat Commun* 2014;5:3156.
- Paschou P, Drineas P, Lewis J, Nievergelt CM, Nickerson DA, Smith JD, et al. Tracing sub-structure in the European American population with PCA-informative markers. *PLoS Genet* 2008;4:e1000114.
- Permeth-Wey J, Chen YA, Tsai YY, Chen ZH, Qu XT, Lancaster JM, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. *Cancer Epidemiol Biomarkers Prev* 2011;20:1131–45.
- Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* 2013;45:362–70.
- Wang K, Li MY, Hadley D, Liu R, Glessner J, Grant SFA, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res* 2007;17:1665–74.
- Diskin SJ, Li MY, Hou CP, Yang SZ, Glessner J, Hakonarson H, et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. *Nucleic Acids Res* 2008;36:e126.
- Kim JH, Hu HJ, Yim SH, Bae JS, Kim SY, Chung YJ. CNVRuler: a copy number variation-based case-control association analysis tool. *Bioinformatics* 2012;28:1790–2.
- Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu FL, et al. Integrating common and rare genetic variation in diverse human populations. *Nature* 2010;467:52–8.
- Glessner JT, Li J, Hakonarson H. ParseCNV integrative copy number variation association software with quality tracking. *Nucleic Acids Res* 2013;41:e64.
- Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. *Nat Rev Genet* 2015;16:172–83.
- Schwiebacher C, De Grandi A, Fuchsberger C, Facheris MF, Svaldi M, Wjst M, et al. Copy number variation and association over T-cell receptor genes—influence of DNA source. *Immunogenetics* 2010;62:561–7.
- Tomlinson IM, Cook GP, Carter NP, Elavarapu R, Smith S, Walter G, et al. Human immunoglobulin VH and D segments on chromosomes 15q11.2 and 16p11.2. *Hum Mol Genet* 1994;3:853–60.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011;474:609–15.
- Li QY, Seo JH, Stranger B, McKenna A, Pe'er I, LaFramboise T, et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. *Cell* 2013;152:633–41.
- Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134–40.
- Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. *Cell* 2013;155:934–47.
- Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science* 2015;347:1260419.
- Zhou Y, Shen JK, Hornicek FJ, Kan Q, Duan Z. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. *Oncotarget* 2016;7:40846–59.
- Petretti C, Savoian M, Montebault E, Glover DM, Prigent C, Giet R. The PITSLRE/CDK11(p58) protein kinase promotes centrosome maturation and bipolar spindle formation. *EMBO Rep* 2006;7:418–24.
- Liu XZ, Gao Y, Shen JS, Yang W, Choy E, Mankin H, et al. Cyclin-dependent kinase 11 (CDK11) is required for ovarian cancer cell growth in vitro and in vivo, and its inhibition causes apoptosis and sensitizes cells to paclitaxel. *Mol Cancer Ther* 2016;15:1691–701.
- Zong HL, Chi YY, Wang YL, Yang YZ, Zhang L, Jiang JH, et al. Cyclin D3/CDK11(p58) complex is involved in the repression of androgen receptor. *Mol Cell Biol* 2007;27:7125–42.
- Chi YY, Hong Y, Zong HL, Wang YL, Zou WY, Yang JW, et al. CDK11(p58) represses vitamin D receptor-mediated transcriptional activation through promoting its ubiquitin-proteasome degradation. *Biochem Biophys Res Commun* 2009;386:493–8.
- Wang YL, Zong HL, Chi YY, Hong Y, Yang YZ, Zou WY, et al. Repression of estrogen receptor alpha by CDK11(p58) through promoting its ubiquitin-proteasome degradation. *J Biochem* 2009;145:331–43.
- Chi Y, Huang S, Wang L, Zhou R, Wang L, Xiao X, et al. CDK11p58 inhibits ER α -positive breast cancer invasion by targeting integrin β 3 via the repression of ER α signaling. *BMC Cancer* 2014;14:577.
- Nakano M, Fukushima Y, Yokota S, Fukami T, Takamiya M, Aoki Y, et al. CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126(star). *Drug Metab Dispos* 2015;43:703–12.
- Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. *Drug Metab Rev* 2002;34:83–448.
- Liu YL, Xu Y, Li F, Chen H, Guo SL. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. *Tumor Biol* 2013;34:2651–7.
- Ortmann B, Bensaddek D, Carvalhal S, Moser SC, Mudie S, Griffin ER, et al. CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cells. *J Cell Sci* 2016;129:191–205.
- Thean LF, Wong YH, Lo M, Loi C, Chew MH, Tang CL, et al. Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B

- lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. *PLoS One* 2017;12:e0173772.
41. Riechers A, Bosserhoff AK. Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large. *Exp Dermatol* 2014;23:12-4.
 42. El Fitori J, Kleeff J, Giese NA, Guweidhi A, Bosserhoff AK, Buchler MW, et al. Melanoma inhibitory activity (MIA) increases the invasiveness of pancreatic cancer cells. *Cancer Cell Int* 2005;5:3.
 43. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. *Endocr Rev* 2007;28:440-61.
 44. Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. *PLoS ONE* 2012;7:e30996.
 45. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresistant disease. *Gene Chromosome Canc* 2007;46:1-9.
 46. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. *Tumori* 2009;95:357-66.
 47. Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR, et al. Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. *Gynecol Oncol* 1999;74:98-102.
 48. Broad Institute TCGA Genome Data Analysis Center. SNP6 copy number analysis (GISTIC2). Cambridge, MA: Broad Institute of MIT and Harvard; 2016.
 49. Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andre V, Marzagalli M, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. *Hum Reprod Update* 2016;22:358-81.
 50. Grundker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. *Front Endocrinol* 2017;8:187.
 51. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, et al. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecol Oncol* 2015;136:542-8.
 52. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 2009;41:1127-32.
 53. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. *Int J Cancer* 2006;118:1426-9.
 54. Davies S, Holmes A, Lomo L, Steinkamp MP, Kang H, Muller CY, et al. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. *Int J Gynecol Pathol* 2014;33:402-10.
 55. Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, et al. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. *BMC Cancer* 2016;16:138.
 56. Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, et al. ERBB4 expression in ovarian serous carcinoma resistant to platinum-based therapy. *Cancer Control* 2017;24:89-95.
 57. Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R, Elenius K. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. *Gynecol Oncol* 2013;129:179-87.
 58. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. *Hum Mol Genet* 2007;16:129-41.
 59. Glunde K, Bhujwala ZM, Ronen SM. Choline metabolism in malignant transformation. *Nat Rev Cancer* 2011;11:835-48.
 60. Yoon JH, Her S, Kim M, Jang IS, Park J. The expression of damage-regulated autophagy modulator 2 (DRAM2) contributes to autophagy induction. *Mol Biol Rep* 2012;39:1087-93.
 61. Park SM, Kim K, Lee EJ, Kim BK, Lee TJ, Seo T, et al. Reduced expression of DRAM2/TMEM77 in tumor cells interferes with cell death. *Biochem Biophys Res Commun* 2009;390:1340-4.
 62. Franchini C, Fontana F, Minuzzo M, Babbio F, Privitera E. Apoptosis promoted by up-regulation of TFPT (TCF3 fusion partner) appears p53 independent, cell type restricted and cell density influenced. *Apoptosis* 2006;11:2217-24.
 63. Liu HP, Chen CC, Wu CC, Huang YC, Liu SC, Liang Y, et al. Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate CDC42 and thereby promote migration of nasopharyngeal carcinoma cells. *PLoS Pathogens* 2012;8:e1002690.
 64. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. *Clin Cancer Res* 2005;11:2149-55.
 65. Mace A, Tuke MA, Deelen P, Kristiansson K, Mattsson H, Noukas M, et al. CNV-association meta-analysis in 191,161 European adults reveals new loci associated with anthropometric traits. *Nat Commun* 2017;8:744.